OUR CLINICAL TRIAL
Bringing RNA epigenetics into the clinic
The first-in-patient study of EP102, our lead METTL3 inhibitor, marks a major milestone for EPICS Therapeutics, and for the field of RNA epigenetics.
Focused on cancers of high unmet need
EPICS is prioritizing cancers where METTL3 dysregulation and DNA damage response pathways intersect, a setting where existing therapies are often insufficient.
- NSCLC: Despite advances in targeted and immune therapies, many patients relapse, highlighting a need for new mechanisms of action.
- Pancreatic cancer: Among the deadliest cancers, with limited effective therapies and a 5-year relative survival of 3%
- Ovarian cancer: High recurrence rates and resistance to standard regimens create urgent unmet needs.
- Colorectal cancer: A leading cause of cancer mortality, where treatment resistance and disease progression remain major clinical challenges. By targeting METTL3, EP102 introduces a new mechanism of action aimed at restoring control over tumor growth and treatment resistance.
Where the study is being conducted
- Up to 12 clinical sites across Spain, Czech Republic, Belgium, and The Netherlands
- Status: multiple cohorts have initiated treatment; study to include up to 78 patients
- Preliminary readout: safety and pharmacokinetic data expected in 2026
EU Clinical Trials Information System (CTIS) ID: EU CT # 2025-521305-40
Clinicaltrials.gov ID: NCT07163325
“Our focus today is clear: bring EP102 through clinical validation and build from that foundation toward a new generation of RNA–directed cancer medicines.”